Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

46.40 +1.26 (+2.78%)

Streaming Delayed Price Updated: 1:33 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

41 42 Next >

Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval ↗

March 06, 2023

The French drug company got the nod for a hemophilia treatment.

Via The Motley Fool

FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles ↗

March 01, 2023

Via Benzinga

Eli Lilly Slashes Insulin Prices By 70%, Will Other Insulin Makers Follow Suit? ↗

March 01, 2023

Eli Lilly & Co (NYSE: LLY), in an effort to make it easier for patients to access affordable insulin and navigate the complex healthcare system, announced on Wednesday a 70% reduction in the list price...

Via Benzinga

The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks ↗

February 24, 2023

Startling cancer vaccine results from Moderna may point to the next big thing in biotech.

Via Investor's Business Daily

FDA Approves Sanofi's Hemophilia A Therapy Offering Significant Bleed Protection ↗

February 24, 2023

Via Benzinga

Sanofi (SNY) Q4 2022 Earnings Call Transcript ↗

February 03, 2023

SNY earnings call for the period ending December 31, 2022.

Via The Motley Fool

Earnings Outlook For Sanofi ↗

February 02, 2023

Via Benzinga

Hopeful Golden Cross Forms On Sanofi's Chart ↗

January 26, 2023

Via Benzinga

Analyst Confidence in Eli Lilly Boosted by Product Pipeline

February 22, 2023

Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term.

Via MarketBeat

Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees ↗

February 17, 2023

Shares crumbled after Moderna's flu shot outperformed in just one flu strain.

Via Investor's Business Daily

Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review ↗

February 03, 2023

The major indexes continued to run despite mixed-to-weak earnings.

Via Investor's Business Daily

BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results ↗

February 03, 2023

Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony...

Via Benzinga

Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples ↗

February 03, 2023

Regeneron beat forecasts despite wide declines. But Sanofi fell on its mixed report.

Via Investor's Business Daily

Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact ↗

February 03, 2023

Trading in the U.S. index futures suggests stocks may end a solidly positive week on a negative note. That said, the data-dependency of the Fed places the onus of providing trading cues to each...

Via Benzinga

Sanofi Expects Moderate 2023 Profit Growth On Dupixent Demand, But Dampened By Aubagio Generics Competition ↗

February 03, 2023

Via Benzinga

Alphabet, Apple And 3 Stocks To Watch Heading Into Friday ↗

February 03, 2023

With Nasdaq stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Fear & Greed Index Remains In 'Greed' Zone As Nasdaq Record Sharp Gains For Fourth Straight Week ↗

February 03, 2023

The CNN Money Fear and Greed index showed some decline in overall sentiment among US investors. US stocks closed mostly higher on Thursday, with the tech-laden Nasdaq index leading the rally. Investors...

Via Benzinga

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

Sanofi Layoffs 2023: What to Know About the Latest SNY Job Cuts ↗

January 31, 2023

One French pharmaceutical producer is implementing job cuts. Here's what investors need to know about the Sanofi layoffs.

Via InvestorPlace

Sanofi Might Pull Down Shutters For Two Vaccine Plants In India ↗

January 30, 2023

After Sanofi SA (NASDAQ: SNY) failed to secure a UNICEF contract, the company is weighing closing operations at two of its vaccine-making facilities in Hyderabad, India, and plans to let go of all...

Via Benzinga

Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis ↗

January 30, 2023

Via Benzinga

Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis

January 30, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Could This Vaccine Become Sanofi's Latest Blockbuster? ↗

January 29, 2023

This vaccine candidate could be approved in newborns and infants later this year.

Via The Motley Fool

7 Blue-Chip Stocks to Buy as a New Bull Market Emerges ↗

January 26, 2023

Many blue-chip stocks look like a bargain right now, and these seven companies are certainly no exception.

Via InvestorPlace

Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch ↗

January 29, 2023

With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.

Via Benzinga

Mergers and Acquisitions in 2023 Off To A Strong Start

January 26, 2023

Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.

Via MarketBeat

Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023 ↗

January 23, 2023

It's difficult to imagine a future where healthcare isn't in high demand.

Via The Motley Fool

Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market ↗

January 19, 2023

After years of lab failures, the companies could crack open a multibillion-dollar market.

Via Investor's Business Daily

The Viral “Tripledemic” Opportunity ↗

January 14, 2023

Between Covid, the flu, and RSV, investors in over-the-counter consumer pharmaceutical companies might be wondering if now is a logical time to up their holdings in the companies that make cold and flu...

Via Talk Markets

Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot ↗

January 13, 2023

Johnson & Johnson (NYSE: JNJ) has significantly scaled back its efforts of manufacturing its COVID-19 vaccine after facing a fall in demand.

Via Benzinga

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.